Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Glycated hemoglobin(HbA1c) values (National Glycohemoglobin Standardization Program : NGSP) ≤10.5%~* estimated glomerular filtration rate(eGFR) of ≥30 mL/min/1.73 m2~* The median UACR of the first morning void urine samples is ≥50 mg/g Cr and \<300 mg/g Cr~* Stable blood pressure(diastolic blood pressure (DBP) \<100 mmHg and stable systolic blood pressure (SBP) \<160 mmHg)~Exclusion Criteria:~* Type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes.~* A diagnosis of non-diabetic renal disease.~* A following serum potassium level.~  * eGFR of 30-59mL/min/1.73m2; serum potassium level of \<3.5 or \>4.7 mmol/L,~ * eGFR of ≥60mL/min/1.73m2: serum potassium level of \<3.5 or \>5.0 mmol/L~* symptomatic and clinically significant hypotension(diastolic blood pressure(DBP)\<50mmHg and systolic blood pressure(SBP)\<110mmHg)~* QT prolongation or torsades de pointes, or, a history or family history of QT prolongation or torsades de pointes~* New York Heart Association (NYHA) Class III or IV heart failure

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MT-3995 Low (Type: EXPERIMENTAL): None
- MT-3995 Middle (Type: EXPERIMENTAL): None
- MT-3995 High (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).